U.S. markets close in 30 minutes
  • S&P 500

    4,101.06
    -35.42 (-0.86%)
     
  • Dow 30

    33,810.84
    -115.17 (-0.34%)
     
  • Nasdaq

    11,853.70
    -153.26 (-1.28%)
     
  • Russell 2000

    1,953.90
    -31.64 (-1.59%)
     
  • Crude Oil

    74.39
    +1.00 (+1.36%)
     
  • Gold

    1,879.60
    +3.00 (+0.16%)
     
  • Silver

    22.26
    -0.14 (-0.62%)
     
  • EUR/USD

    1.0731
    -0.0066 (-0.61%)
     
  • 10-Yr Bond

    3.6340
    +0.1020 (+2.89%)
     
  • GBP/USD

    1.2026
    -0.0030 (-0.25%)
     
  • USD/JPY

    132.6230
    +1.4730 (+1.12%)
     
  • BTC-USD

    23,002.63
    +77.36 (+0.34%)
     
  • CMC Crypto 200

    528.85
    +3.71 (+0.71%)
     
  • FTSE 100

    7,836.71
    -65.09 (-0.82%)
     
  • Nikkei 225

    27,693.65
    +184.19 (+0.67%)
     

Perma-Fix Reports Over 20% Increase in Revenue to $19.5 Million for the Second Quarter of 2022

Perma-Fix Environmental Services, Inc
Perma-Fix Environmental Services, Inc

Reports sequential and year-over-year revenue growth in both the Treatment and Services Segments

ATLANTA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the second quarter ended June 30, 2022.

Mark Duff, President and CEO of the Company, commented, “We achieved a 20.5% increase in revenue to $19.5 million and a 198.6% increase in gross profit for the second quarter of 2022, compared to the same period last year. Importantly, for the second quarter of 2022, we achieved sequential and year-over-year revenue growth in both our Treatment and Services Segments. This growth was due in part to the resumption of work and attaining complete operational levels on several projects within our Services Segment, which had been delayed due to the impact of COVID-19 pandemic. Within our Treatment Segment, we benefitted from a 54% increase in waste receipts, including both commercial and international waste.

“We are witnessing increased requests for proposals within both the government and commercial sectors, as well as international customers. Moreover, our ability to provide innovative solutions, including both waste management and radiological contamination, has supported our ability to join teams on larger strategic bids. Within our Treatment Segment we are seeing improvement in our project backlog, including expanded treatment services to the commercial utility sector. Our Test Bed Initiative (TBI) program also continues to progress with Nuclear Regulatory Commission (NRC) approval of the Department of Energy’s (DOE) Waste Incidental to Reprocessing report, which we believe opens the door to commence shipment of the next 2,000 gallons to our facility, which we are hopeful will occur before year-end. Overall, we remain encouraged by the outlook for the business given the pace of waste treatment receipts, new bidding opportunities, and improved federal budgets.”

Financial Results

Revenue for the second quarter of 2022 was approximately $19.5 million versus approximately $16.1 million for the same period last year. Services Segment revenue increased to approximately $11.1 million for the three months ended June 30, 2022 from $8.4 million for the corresponding period of 2021 due to resumed/increased work under certain projects which had been delayed/curtailed due to COVID-19 impact and/or administrative delays experienced by certain customers. These projects were awarded to us in the second quarter of 2021. Revenue for the Treatment Segment was approximately $8.4 million and $7.7 million for the second quarter of 2022 and 2021, respectively. The increase was primarily due to improvement in waste receipts from certain customers who have delayed waste shipments due, in part, to the impact of COVID-19. This improvement is reflected in our Treatment Segment waste backlog of $7,169,000 at June 30, 2022, an increase of approximately $1,048,000 from the balance of $6,121,000 at March 31, 2022.

Gross profit for the second quarter of 2022 was $2.9 million versus $966,000 for the second quarter of 2021 primarily due to higher revenue generated in both segments.

Operating loss for the second quarter of 2022 was approximately $880,000 versus operating loss of $2.2 million for the second quarter of 2021. Net loss attributable to common stockholders for the second quarter of 2022 was approximately $1.4 million or ($0.11) per basic share versus net income attributed to common stockholders for the second quarter of 2021 of approximately $3.0 million or $0.25 per basic share. Net income attributable to common stockholders for the second quarter of 2022 included a tax expense of $347,000 which was primarily driven by our change in forecasted income for the year. Net income attributable to common stockholders for the second quarter of 2021 included a “Gain on extinguishment of debt” recorded in the amount of approximately $5.4 million resulting from the Paycheck Protection Program (“PPP”) Loan that was forgiven by the U.S. Small Business Administration in June 2021.

The Company reported Adjusted EBITDA of ($403,000) from continuing operations for the quarter ended June 30, 2022, as compared to Adjusted EBITDA of ($1.7) million from continuing operations for the same period of 2021. The Company defines EBITDA as earnings before interest, taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA before research and development costs related to the Medical Isotope project and gain on extinguishment of debt. As previously disclosed, in December 2021, the Company made the strategic decision to cease all research and development (“R&D”) activities under the Medical Segment and sold 100% of its interest in Perma-Fix Medical S.A., which comprised its Medical Segment. Both EBITDA and Adjusted EBITDA are not measures of performance calculated in accordance with Generally Accepted Accounting Principles in the United States of America (GAAP), and should not be considered in isolation of, or as a substitute for, earnings as an indicator of operating performance or cash flows from operating activities as a measure of liquidity. The Company believes the presentation of EBITDA and Adjusted EBITDA is relevant and useful by enhancing the readers’ ability to understand the Company’s operating performance. The Company’s management utilizes EBITDA and Adjusted EBITDA as a means to measure performance. The Company’s measurements of EBITDA and Adjusted EBITDA may not be comparable to similar titled measures reported by other companies. The table below reconciles EBITDA and Adjusted EBITDA, both non-GAAP measures, to GAAP numbers for (loss) income from continuing operations for the three and six months ended June 30, 2022 and 2021.

 

 

(Unaudited)

 

(Unaudited)

 

 

Three Months Ended

 

Six Months Ended

 

 

June 30,

 

June 30,

(In thousands)

 

2022

 

2021

 

2022

 

2021

(Loss) income from continuing operations

 

$

(1,257

)

$

3,121

 

 

$

(2,506

)

$

2,083

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjustments:

 

 

 

 

 

 

 

 

Depreciation & amortization

 

 

480

 

 

 

400

 

 

 

936

 

 

 

799

 

Interest income

 

 

(29

)

 

 

(2

)

 

 

(40

)

 

 

(21

)

Interest expense

 

 

41

 

 

 

65

 

 

 

76

 

 

 

132

 

Interest expense - financing fees

 

 

15

 

 

 

9

 

 

 

28

 

 

 

17

 

Income tax expense (benefit)

 

 

347

 

 

 

13

 

 

 

(326

)

 

 

(4

)

 

 

 

 

 

 

 

 

 

EBITDA

 

 

(403

)

 

 

3,606

 

 

 

(1,832

)

 

 

3,006

 

 

 

 

 

 

 

 

 

 

Gain on extinguishment of debt

 

 

 

(5,381

)

 

 

 

(5,381

)

 

 

 

 

 

 

 

 

 

Research and development costs related to

 

 

 

 

 

 

 

Medical Isotope project

 

 

 

72

 

 

 

 

149

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

$

(403

)

 

$

(1,703

)

 

$

(1,832

)

 

$

(2,226

)

 

 

 

 

 

 

 

 

 

The tables below present certain unaudited financial information for the business segments, which excludes allocation of corporate expenses. As noted above, in December 2021, the Company made the strategic decision to cease all R&D activities under the Medical Segment and sold 100% of its interest in Perma-Fix Medical S.A., which comprised of its Medical Segment.

 

 

Three Months Ended

 

Six Months Ended

 

 

June 30, 2022

 

June 30, 2022

 

 

(Unaudited)

 

(Unaudited)

(In thousands)

 

Treatment

 

Services

 

Treatment

 

Services

Net revenues

 

$

8,393

 

$

11,062

 

$

15,872

 

$

19,498

Gross profit

 

 

1,563

 

 

1,321

 

 

2,201

 

 

2,319

Segment profit

 

 

60

 

 

472

 

 

137

 

 

871

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

Three Months Ended

 

Six Months Ended

 

 

June 30, 2021

 

June 30, 2021

 

 

 

 

(Unaudited)

 

 

 

(Unaudited)

(In thousands)

 

Treatment

 

Services

 

 

Medical

 

Treatment

 

Services

 

 

Medical

Net revenues

 

$

7,706

 

$

8,439

 

 

$

 

$

15,201

 

$

24,077

 

 

$

Gross profit (negative gross profit)

 

 

1,433

 

 

(467

)

 

 

 

 

2,358

 

 

964

 

 

 

Segment profit (loss)

 

 

468

 

 

(1,302

)

 

 

(72

)

 

 

366

 

 

(747

)

 

 

(149

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COVID-19

The Company continues to proactively update its ongoing business operations and safety plans, which we believe will mitigate any potential impact of COVID-19. However, as the situations surrounding COVID-19 remain fluid, the full impact and extent of the pandemic on the Company’s financial results cannot be estimated with any degree of certainty.

Conference Call

Perma-Fix will host a conference call at 11:00 a.m. ET on Friday, August 5, 2022. The call will be available on the Company’s website at www.perma-fix.com, or by calling toll free 877-545-0320 for U.S. callers, or +1 973-528-0002 for international callers and by entering access code: 963791. The conference call will be led by Mark J. Duff, Chief Executive Officer, Dr. Louis F. Centofanti, Executive Vice President of Strategic Initiatives, and Ben Naccarato, Executive Vice President and Chief Financial Officer of Perma-Fix Environmental Services, Inc.

A webcast will also be archived on the Company’s website and a telephone replay of the call will be available approximately one hour following the call, through Friday, August 12, 2022, and can be accessed by calling: 877-481-4010 for U.S. callers, or +1 919-882-2331 for international callers and entering conference ID: 46310.

About Perma-Fix Environmental Services

Perma-Fix Environmental Services, Inc. is a nuclear services company and leading provider of nuclear and mixed waste management services. The Company's nuclear waste services include management and treatment of radioactive and mixed waste for hospitals, research labs and institutions, federal agencies, including the DOE, the U.S Department of Defense (“DOD”), and the commercial nuclear industry. The Company’s nuclear services group provides project management, waste management, environmental restoration, decontamination and decommissioning, new build construction, and radiological protection, safety and industrial hygiene capability to our clients. The Company operates four nuclear waste treatment facilities and provides nuclear services at DOE, DOD, and commercial facilities, nationwide.

Please visit us at http://www.perma-fix.com.

This press release contains “forward-looking statements” which are based largely on the Company's expectations and are subject to various business risks and uncertainties, certain of which are beyond the Company's control. Forward-looking statements generally are identifiable by use of the words such as “believe”, “expects”, “intends”, “anticipate”, “plans to”, “estimates”, “projects”, and similar expressions. Forward-looking statements include, but are not limited to: shipment of the next 2,000 gallons before year-end and outlook. These forward-looking statements are intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. While the Company believes the expectations reflected in this news release are reasonable, it can give no assurance such expectations will prove to be correct. There are a variety of factors which could cause future outcomes to differ materially from those described in this release, including, without limitation, future economic conditions; industry conditions; competitive pressures; our ability to apply and market our new technologies; the government or such other party to a contract granted to us fails to abide by or comply with the contract or to deliver waste as anticipated under the contract; inability to win bid projects; failure of Congress to provides continuing funding for the DOD’s and DOE’s remediation projects; ability to obtain new foreign and domestic remediation contracts; inability to meet financial covenants; impact of COVID-19; and the “Risk Factors” discussed in, and the additional factors referred to under "Special Note Regarding Forward-Looking Statements" of, our 2021 Form 10-K and Form 10-Q for quarters ended March 31, 2022 and June 30, 2022. The Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that bear upon forward-looking statements.

FINANCIAL TABLES FOLLOW

Contacts:
David K. Waldman-US Investor Relations
Crescendo Communications, LLC
(212) 671-1021

Herbert Strauss-European Investor Relations
herbert@eu-ir.com
+43 316 296 316

PERMA-FIX ENVIRONMENTAL SERVICES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

 

 

Three Months Ended

 

Six Months Ended

 

 

June 30,

 

June 30,

(Amounts in Thousands, Except for Per Share Amounts)

 

2022

 

2021

 

2022

 

2021

 

 

 

 

 

 

 

 

 

Net revenues

$

19,455

 

$

16,145

 

$

35,370

 

$

39,278

 

Cost of goods sold

 

16,571

 

 

15,179

 

 

30,850

 

 

35,956

 

Gross profit

 

2,884

 

 

966

 

 

4,520

 

 

3,322

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

3,684

 

 

2,997

 

 

7,106

 

 

6,202

 

Research and development

 

80

 

 

144

 

 

176

 

 

295

 

Loss on disposal of property and equipment

 

 

 

1

 

 

Loss from operations

 

(880

)

 

(2,175

)

 

(2,763

)

 

(3,175

)

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

 

Interest income

 

29

 

 

2

 

 

40

 

 

21

 

Interest expense

 

(41

)

 

(65

)

 

(76

)

 

(132

)

Interest expense-financing fees

 

(15

)

 

(9

)

 

(28

)

 

(17

)

Other

 

(3

)

 

 

(5

)

 

1

 

Gain on extinguishment of debt

 

 

5,381

 

 

 

5,381

 

(Loss) income from continuing operations before taxes

 

(910

)

 

3,134

 

 

(2,832

)

 

2,079

 

Income tax expense (benefit)

 

347

 

 

13

 

 

(326

)

 

(4

)

(Loss) income from continuing operations, net of taxes

 

(1,257

)

 

3,121

 

 

(2,506

)

 

2,083

 

 

 

 

 

 

 

 

 

 

Loss from discontinued operations (net of taxes)

 

(188

)

 

(127

)

 

(282

)

 

(242

)

Net (loss) income

 

(1,445

)

 

2,994

 

 

(2,788

)

 

1,841

 

 

 

 

 

 

 

 

 

 

Net loss attributable to non-controlling interest

 

 

(29

)

 

 

(59

)

 

 

 

 

 

 

 

 

 

Net (loss) income attributable to Perma-Fix Environmental

 

 

 

 

 

 

 

 

Services, Inc. common stockholders

$

(1,445

)

$

3,023

 

$

(2,788

)

$

1,900

 

 

 

 

 

 

 

 

 

 

Net (loss) income per common share attributable to Perma-Fix

 

 

 

 

 

 

 

 

Environmental Services, Inc. stockholders - basic:

 

 

 

 

 

 

 

 

Continuing operations

$

(.10)

$

.26

$

(.19)

$

.18

Discontinued operations

 

(.01)

 

(.01)

 

(.02)

 

(.02)

Net (loss) income per common share

$

(.11)

$

.25

$

(.21)

$

.16

 

 

 

 

 

 

 

 

 

Net (loss) income per common share attributable to Perma-Fix

 

 

 

 

 

 

 

 

Environmental Services, Inc. stockholders - diluted:

 

 

 

 

 

 

 

 

Continuing operations

$

(.10)

$

.25

$

(.19)

$

.17

Discontinued operations

 

(.01)

 

(.01)

 

(.02)

 

(.02)

Net (loss) income per common share

$

(.11)

$

.24

$

(.21)

$

.15

 

 

 

 

 

 

 

 

 

Number of common shares used in computing

 

 

 

 

 

 

 

 

net (loss) income per share:

 

 

 

 

 

 

 

 

Basic

 

13,264

 

 

12,180

 

 

13,249

 

 

12,173

 

Diluted

 

13,264

 

 

12,440

 

 

13,249

 

 

12,420

 

 

 

 

 

 

 

 

 

 

 

PERMA-FIX ENVIRONMENTAL SERVICES, INC.
CONSOLIDATED BALANCE SHEETS

 

 

June 30,

 

December 31,

 

 

2022

 

2021

(Amounts in Thousands, Except for Share and Per Share Amounts)

 

(Unaudited)

 

(Audited)

 

 

 

 

 

ASSETS

 

 

 

 

Current assets:

 

 

 

 

Cash

 

$

163

 

 

$

4,440

 

Account receivable, net of allowance for doubtful

 

 

 

 

accounts of $30 and $85, respectively

 

12,956

 

 

 

11,372

 

Unbilled receivables

 

 

6,348

 

 

 

8,995

 

Other current assets

 

 

4,197

 

 

 

5,152

 

Assets of discontinued operations included in current assets

 

 

17

 

 

 

15

 

Total current assets

 

 

23,681

 

 

 

29,974

 

 

 

 

 

 

Net property and equipment

 

 

18,991

 

 

 

18,609

 

Property and equipment of discontinued operations

 

 

81

 

 

 

81

 

 

 

 

 

 

Operating lease right-of-use assets

 

 

2,202

 

 

 

2,460

 

 

 

 

 

 

Intangibles and other assets

 

 

26,193

 

 

 

26,177

 

Total assets

 

$

71,148

 

 

$

77,301

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS� EQUITY

 

 

 

 

Current liabilities

 

$

21,646

 

 

$

25,408

 

Current liabilities related to discontinued operations

 

 

914

 

 

 

506

 

Total current liabilities

 

 

22,560

 

 

 

25,914

 

 

 

 

 

 

Long-term liabilities

 

 

10,120

 

 

 

10,126

 

Long-term liabilities related to discontinued operations

 

 

265

 

 

 

677

 

Total liabilities

 

 

32,945

 

 

 

36,717

 

Commitments and Contingencies

 

 

 

 

Stockholders� equity:

 

 

 

 

Preferred Stock, $.001 par value; 2,000,000 shares authorized,

 

 

 

 

no shares issued and outstanding

 

 

Common Stock, $.001 par value; 30,000,000 shares authorized,

 

 

 

 

13,280,265 and 13,222,552 shares issued, respectively;

 

 

 

 

13,272,623 and 13,214,910 shares outstanding, respectively

 

 

13

 

 

 

13

 

Additional paid-in capital

 

 

114,755

 

 

 

114,307

 

Accumulated deficit

 

 

(76,408

)

 

 

(73,620

)

Accumulated other comprehensive loss

 

 

(69

)

 

 

(28

)

Less Common Stock held in treasury, at cost: 7,642 shares

 

 

(88

)

 

 

(88

)

Total stockholders' equity

 

 

38,203

 

 

 

40,584

 

 

 

 

 

 

Total liabilities and stockholders' equity

 

$

71,148

 

 

$

77,301